SCHEMBL8312951

SCHEMBL8312951

COC(OC)c1cc(-c2cccc(N)c2)n(C)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 2/20 0.37
CCNT1 O60563 2/20 0.37
CCNA2 P20248 2/20 0.37
CDK2 P24941 2/20 0.37
CDK9 P50750 2/20 0.37
CDK5 Q00535 2/20 0.37
DYRK1A Q13627 2/20 0.37
CDK5R1 Q15078 2/20 0.37
DYRK2 Q92630 2/20 0.37
DYRK1B Q9Y463 2/20 0.37
MAOA P21397 1/20 0.36
MAP4K4 O95819 4/20 0.35
FYN P06241 3/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
PSIP1 O75475 1/20 0.34
AXL P30530 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5389872 0.81 DYRK1A (0.38) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL5389145 0.81 CLK4 (0.41)
SCHEMBL5389869 0.77 FYN (0.37) FYN
SCHEMBL3342646 0.75 MAP4K4 (0.42) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL5097619 0.75 KMT2A (0.40) FYNMEN1CYP3A4MKNK1POLB
SCHEMBL22353993 0.72 MAPK14 (0.40) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL980384 0.67 PIK3CD (0.50) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL23142760 0.67 MAOA (0.52) DYRK3CCNT1CCNA2CDK2CDK9
SCHEMBL16386822 0.66 DDB1 (0.42) CDK5CDK5R1ALDH1A1CYP3A4RECQL
SCHEMBL29979572 0.66 TSHR (0.53) DYRK3CCNT1CCNA2CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004089911-A1 PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2004-10-21 WO disclosed